US20030013682A1 - Derivatives of partially desulphated glycosaminologycans endowed with antiangiogenic activity and devoid of anticogulating effect - Google Patents

Derivatives of partially desulphated glycosaminologycans endowed with antiangiogenic activity and devoid of anticogulating effect Download PDF

Info

Publication number
US20030013682A1
US20030013682A1 US10/182,185 US18218502A US2003013682A1 US 20030013682 A1 US20030013682 A1 US 20030013682A1 US 18218502 A US18218502 A US 18218502A US 2003013682 A1 US2003013682 A1 US 2003013682A1
Authority
US
United States
Prior art keywords
heparin
uronic acids
percentage
approximately
partially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/182,185
Other languages
English (en)
Inventor
Casu Banito
Torri Giangiacomo
Naggi Anna Maria
Giannini Giuseppe
Pisano Claudio
Penco Sergio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Assigned to SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. reassignment SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GIANNINI, GIUSEPPE, PISANO, CLAUDIO, CASU, BANITO, GIANGIACOMO, TORRI, NAGGI, ANNA MARIA, PENCO, SERGIO
Publication of US20030013682A1 publication Critical patent/US20030013682A1/en
Priority to US11/028,512 priority Critical patent/US7790700B2/en
Priority to US11/314,736 priority patent/US7781416B2/en
Priority to US11/882,978 priority patent/US8067555B2/en
Priority to US11/980,741 priority patent/US20080139503A1/en
Priority to US12/851,166 priority patent/US8222231B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Definitions

  • the invention described herein relates to partly desulphated glycosaminoglycan derivatives, particularly heparins, to processes for their preparation, to their use as active ingredients for the preparation of medicaments with an antiangiogenic activity, particularly for the treatment of tumours, such as, for example, the metastatic forms, and to pharmaceutical compositions containing them.
  • vasculogenesis that is to say the formation of blood vessels during embryonic development and angiogenesis in the strict sense of the term, meaning the formation of new blood vessels (capillaries) during the postnatal life starting from pre-existing vessels.
  • angiogenesis for the growth of solid tumours is amply documented. Over the past three decades it has been reported that tumour growth, as well as the formation of metastases, are strictly dependent on the development of new vessels capable of vascularising the tumour mass.
  • the inhibition of angiogenesis underlies the formation of necrotic masses within the tumour or the induction of apoptosis in tumour cells.
  • vascular endothelium represents a quiescent tissue with a very low mitotic index of its constituent cells (renewal time measured in hundreds of days), and the vascular network is regular, relatively uniform, and suitable for adequately oxygenating all the tissues, without any arteriovenous connection.
  • tumour tissue on the other hand, stimulation of the proliferation of endothelial cells gives rise to a high mitotic index in the latter (mean renewal time 5 days), the neovascularisation is distinctly irregular with areas of occlusion, sometimes with closed endings, with arteriovenous contacts at some points, and, lastly, the basal membrane presents gaps, which at some points leads to tissue hypoxia.
  • the neovascularisation does not always coincide with a precise stage in the tumour development; there are, in fact, cases in which angiogenesis begins even before the development of the tumour (for example, carcinoma of the uterine cervix), others in which the two phases are coincident (for example, carcinoma of the bladder and breast), and others in which angiogenesis begins after the neoplasm (for example, melanoma and ovarian carcinoma; see, for example, “Manual of Medical Oncology”, IV ed. (1991) G. Bonadonna et al.
  • Antiangiogenic therapy presents numerous advantages compared to traditional standard chemotherapy (Cancer Research 1998, 58, 1408-16):
  • a) specificity its target is a process, i.e. tumour neovascularisation
  • apoptosis blockade of the vascular network in the tumour reduces the supply of oxygen and nutrients to the tumour cells; apoptosis is favoured in these conditions;
  • tumour angiogenesis (Oncology 1997, 54, 177-84).
  • Pro- and anti-angiogenic endogenous factors are known to be involved in the biological regulatory mechanism in the formation of new vessels.
  • fibroblast growth factors FGF
  • VEGF vascular endothelial growth factor
  • TNF- ⁇ tumour necrosis factor- ⁇
  • platelet-derived endothelial cell growth factor transforming growth factor- ⁇
  • an in-vitro inhibitor but an in-vivo stimulator, placental growth factor, interleukin-8, hepatocyte growth factor, platelet-derived growth factor, granulocyte colony-stimulating factors, proliferin, the prostaglandins (PGE 1 , PGE 2 ), GM1-GT1b, substance P, the bradykinins, and nitric oxide.
  • the angiogenesis inhibitors include: the soluble receptor of bFGF, the interferons ( ⁇ , ⁇ , ⁇ ), angiostatin, thrombospondin 1, prolactin (16 kDa terminal amino fragment), platelet factor 4 (PF4), the tissue metalloproteinase (TIMP) inhibitors, placental proliferin-related peptide, glioma-derived angiogenesis inhibition factor, the angiostatic steroids, cartilage-derived inhibitor (CDI), the heparinases, interleukin-12, plasminogen activator inhibitor, the retinoids, endostatin, angiopoietin-2, genistein, nitric oxide and GM3.
  • the interferons ⁇ , ⁇ , ⁇
  • angiostatin thrombospondin 1
  • prolactin (16 kDa terminal amino fragment
  • PF4 platelet factor 4
  • TRIP tissue metalloproteinase
  • the integrins are a vast family of transmembrane proteins that mediate cell-to-cell and cell-to-extracellular matrix interactions. All integrins are capable of recognising a common peptide sequence Arg-Gly-Asp (“universal cell recognition site”), though every integrin preferentially recognises a different conformation of this tripeptide.
  • the inhibition of specific subtypes of integrins can also be of great interest from the pharmacological standpoint for the development of angiogenesis inhibitors.
  • PK-C protein kinase-C
  • angiogenesis There are, in fact, classic PK-C inhibitors capable of completely or partially blocking angiogenesis.
  • a number of drugs are already in Phase III, such as Marimastat (British Biotech.), I'AG3340 (Prinomast-Agouron), and Neovastat (Aeterna), all of which act mainly at the pulmonary level (SNCL) with a mechanism involving interference with the metalloproteinases.
  • RhuMad VEGF this is an anti-VEGF antibody by Genetech
  • interferon a commercial
  • TNP-470 TNP-470
  • drugs such as CAI (NCI) and IM862 (Cytran) are active as antiangiogenic agents but with a non-specific and poorly known mechanism.
  • Heparin is a heterogeneous mixture of naturally occurring polysaccharides of various lengths and various degrees of sulphation which possesses anticoagulant activity and is secreted by the connective tissue mastcells present in the liver (from which it was first isolated), in the muscles, lungs, thymus and spleen.
  • the antitumour and antimetastatic activity of heparin and its derivatives is due to its ability to inhibit heparanase, to block growth factors and to regulate angiogenesis.
  • Heparan sulphates are ubiquitous protein ligands.
  • the proteins bind to the HS chains for a variety of actions from simple immobilisation or protection against the proteolytic degradation action to specific modulations of biological activities, such as angiogenesis.
  • the carbohydrate skeleton in both heparin and the heparan sulphates (HS), consists in an alternation of D-glucosamine (GlcN) and hexuronic acids (Glc.A or IdO.A).
  • HS is also on average less O-sulphated than heparin.
  • heparin in the treatment of angiogenesis disorders, such as tumours, particularly metastases, is substantially limited by the anticoagulant activity of heparin.
  • Heparanases are enzymes belonging to a family of endoglycosidases that hydrolyse the internal glycoside bonds of the chains of heparan sulphates (HS) and heparin.
  • tumour cells are involved in the proliferation of tumour cells, in metastases and in the neovascularisation of tumours. This suggests they may also be involved in tumour angiogenesis as a result of the release, from the extracellular matrix, of growth factors bound to heparin, such as aFGF (also called FGF-1), bFGF (also called FGF-2) and VEGF.
  • FGF also called FGF-1
  • bFGF also called FGF-2
  • heparin derivatives are described obtained by 2-O desulphation or by “glycol split” (oxidation with periodate and subsequent reduction with sodium borohydride). These derivatives, defined here as “2-O-desulphated heparin” and “RO-heparin”, respectively, have partly maintained the antiangiogenic activity of heparin as assessed by means of the CAM test in the presence of corticosteroids, as reported in Table III (ibid. page 360).
  • FGFs regulate multiple physiological processes such as cell growth and differentiation, but also functions involved in pathological processes such as tumour angiogenesis.
  • FGFs are growth factors (a family of more than 10 polypeptides, of which the acid (FGF-1) and basic FGFs (FGF-2) are the ones which have been most studied, which require a polysaccharide cofactor, heparin or HS, to bind to the FGF receptor (FGFR) and activate it.
  • FGF-1 acid
  • FGF-2 basic FGFs
  • FGFR FGF receptor
  • Heparin derivatives with a substantial ability to block heparanase seem to be equally capable of inhibiting angiogenesis both in primary tumours and in metastases.
  • the inhibition of heparanase reduces the migration ability of tumour cells from the primary tumour to other organs.
  • the heparin-like compounds preferably comprise sequences of at least eight monosaccharide units containing N-acetyl-glucosamine-glucuronic acid (or N-sulphated glucosamine (see, for example, D. Sandback-Pikas et al. J. Biol. Chem., 273, 18777-18780 (1998) and references cited).
  • b) blockade of angiogenic growth factors fibroblast type: FGF-1 and FGF-2; vascular endothelium type: VEGF; vascular permeability type: VPF).
  • the heparin-like compounds preferably have sequences at least five monosaccharide units long, containing 2-sulphated iduronic acid and glucosamine N,6-sulphated (see, for example, M. Maccarana et al. J. Biol. Chem., 268, 23989-23905 (1993)).
  • Oligosaccharide fragments with antiangiogenic activity have also been amply described: it has been found, in fact, that by varying the carbohydrate sequence the interaction selectivity can be increased.
  • heparin can be used as a vehicle for substances which are themselves antiangiogenic, such as some steroids, exploiting the affinity of heparin for vascular endothelial cells; see, for example, WO 93/18793 of the University of Texas and Imperial Cancer Research Technology, where heparins are claimed with acid-labile linkers, such as adipic acid hydrazine, bound to cortisol.
  • acid-labile linkers such as adipic acid hydrazine
  • EP 0 246 654 by Daiichi Sc. describes sulphated polysaccharides with antiangiogenic activity with Phase II studies.
  • EP 0 394 971 by Pharmacia & Upjohn Harvard Coll. describes hexa-saccharides—heparin fragments—with low sulphation, capable of inhibiting the growth of endothelial cells and angiogenesis stimulated by (FGF-1).
  • EP 0 618 234 by Alfa Wasserman describes a method for preparing semisynthetic glycosaminoglycans with a heparin or heparan structure bearing a nucleophilic group.
  • WO 95/05182 by Glycomed describes various sulphated oligosaccharides with anticoagulant, antiangiogenic and anti-inflammatory activity.
  • U.S. Pat. No. 5,808,021 by Glycomed describes a method for preparing substantially non-depolymerised 2-O, 3-O desulphated heparin with a desulphation percentage in positions 2- of the iduronic acid (I, 2-O) and in position 3 of the glucosamine unit (A, 3-O) ranging from approximately 99 to approximately 75% of the original percentage.
  • This method envisages desulphation conducted in the presence of a cation of a bivalent metal, exemplified by calcium or copper, followed by lyophilisation of the product obtained.
  • the desulphated heparins have antiangiogenic activity.
  • the aim of the invention described herein is to find optimal glycosaminoglycan structures for generating antiangiogenic activity based on heparanase inhibition and/or FGF growth factor inhibition mechanisms.
  • An additional aim of the invention described herein is to provide a medicament with antiangiogenic activity which is essentially devoid of the typical side effects of heparin derivatives, such as, for example, anticoagulant activity.
  • glycosaminoglycan such as a heparin-like glycosaminoglycan, heparin or modified heparin, containing glucosamine residues with different degrees of N-desulphation and optional subsequent total or partial N-acetylation
  • 2-O-desulphation treatment of the iduronic units up to a degree of desulphation not greater than 60% of the total uronic units the angiogenic growth factor binding properties are maintained.
  • heparin 2-O-desulphated to not more than 60% of its total uronic units is markedly antiangiogenic.
  • the desulphation conducted in the conditions described in the present invention also produces the formation of iduronic units with an oxyranic ring in position 2,3.
  • the opening of the oxyranic ring in the conditions described in the present invention gives rise to L-iduronic or L-galacturonic units.
  • glycosaminoglycan derivative particularly desulphated heparin, selectively partially desulphated with a desulphation degree not exceeding 60% of the total uronic units; these desulphation gaps reduce the length of the regular sequences constituted by the succession of disaccharide trisulphate units.
  • the invention described herein refers to a formula (I) compound
  • X and X′ which can be the same or different, are an aldehyde group or the —CH 2 -D group, where D is hydroxyl or an amino acid, a peptide or a residue of a carbohydrate or oligosaccharide;
  • R and R 1 which can be the same or different, are an SO 3 or acetyl residue;
  • n and m which can be the same or different, may vary from 1 to 40; the sum of n+m ranges from 6 to 40; the m:n ratio ranges from 10:2 to 1:1.
  • m is greater than or equal to n.
  • n ranges from 40 to 60% of the sum m+n. The symbol indicates that the units marked m and n are statistically distributed along the polysaccharide chain and are not necessarily in sequence.
  • the compounds which are the subject matter of the invention described herein, have interesting antiangiogenic properties, and are therefore useful as active ingredients for the preparation of medicaments for the treatment of pathologies based on abnormal angiogenesis, and particularly for the treatment of metastases.
  • the compounds according to the invention present reduced, if not non-existent anticoagulant properties, thus avoiding or reducing the side effects typical of the heparins.
  • a further advantage stems from the fact that the compounds according to the invention can be characterised with instrumental analytical techniques, such as NMR spectroscopy, thus allowing process control which is absolutely desirable from the industrial point of view.
  • molecular weight (MW) has a very important function when making angiogenesis inhibitors. It is well known, in fact, that a reduction in molecular weight (MW) to values corresponding to penta-saccharide units does not lead to a loss of antiangiogenic activity. On the contrary, it has been established that, beyond a certain length, the heparin chains favour rather than inhibit dimerisation and thus activation of FGF.
  • desulphation degree is the percentage of non-sulphated iduronic acids in relation to total uronic acids originally present in the starting heparin.
  • One initial preferred range for the desulphation percentage is from approximately 40 to approximately 60%.
  • the preferred compound is:
  • step e) partial enzymatic hydrolysis with an enzyme selected from the group consisting of lyase, heparinase, heparitinase, or equivalent of products obtained in step e) to yield oligosaccharides, preferably tetra- or octa-saccharides, with the non-reducing terminal residue consisting of unsaturated iduronic acid, the reducing residue consisting of an N-sulphoglucosamine and containing at least one residue of open iduronic acid; or, alternatively
  • step a) the compound obtained in step a), or the product obtained in step b) is treated by partial enzyme hydrolysis; and, if desired
  • the preferred compound is:
  • heparin partially 2-O-desulphated obtainable by the process described above, where step a) is conducted for 45 min at 60° C. and step b) at 70° C. at pH 7, and having a molecular weight (MW) of 11200, a polydispersion index D of 1.3, a desulphation degree of 1.99 (expressed as the SO 3 ⁇ :COO ⁇ molar ratio), percentage of modified uronic acids compared to total uronic acids of approximately 50% (hereinafter also called ST1514);
  • the molecular weights are determined by HPLC-GPC (high performance liquid chromatography—gel permeation chromatography).
  • the desulphation degree is determined by conductimetry and the percentage of modified uronic acids by 13 C-NMR.
  • MW is the molecular weight
  • D is the polydispersion index expressed as MW/Mn.
  • the starting products are glycosaminoglycans of various origins, preferably naturally occurring heparins. It is also possible to use chemically modified heparins with a percentage content of N,6 disulphate ranging from 0 to 100%. Starting from products with a different 6-O-sulphated glucosamine content, it is possible to modulate the length of the regular sequences between one open iduronic acid and another.
  • glycosaminoglycans according to the invention that present opening of the glycoside ring are conventionally called RO derivatives by those skilled in the field, meaning by this that the glycoside ring has been opened by means of an oxidation action, followed by a reduction (Reduction-Oxidation—RO).
  • This opening of the glycoside ring is also conventionally called “glycol split”, so-called because of the formation of the two primary hydroxy present on the open ring.
  • the compounds referred to herein will also be called “RO” or “Glycol Split” derivatives.
  • formula (I) compounds may also bear equal or different groups, as defined above for X and X′, on the primary hydroxy deriving from glycol split, for example, oligosaccharide or peptide groups, ranging from a single saccharide or amino acid to more than one unit of length, preferably 2 or 3 units.
  • Formula (I) compounds where X and X′ are —CH 2 OH can also be used as vehicles for other types of drugs, by means of suitable binding with the heparin portion which is capable of providing a stable bond in normal conditions of manufacture and storage of a formulated drug. which, however, releases the transported drug in the body, preferably in the vicinity of the target organ.
  • drugs that can be transported are steroidal and non-steroidal anti-inflammatory drugs, corticosteroids, and other drugs with an antimetastatic action, in which case there will be an advantageous enhancement of the antimetastatic effect as a result of the sum of the separate intrinsic activities of the compounds according to the invention and the antimetastatic agent bound thereto, with the related advantages of a greater target selectivity and lower systemic toxicity.
  • examples of these drugs are the metalloproteinase inhibitors.
  • Other drugs which can be usefully transported are those that act at the endothelial level.
  • Formula (I) compounds where X and X′ are other than hydroxy or aldehyde can also be used as vehicles for drugs, in which case the X and X′ groups will act as “spacers” between the transported molecule, that is to say the glycosaminoglycan of the present invention and the molecule acting as the vehicle, in those cases where this may be desirable for reasons of pharmacokinetics or pharmacodynamics.
  • heparin In the case of compounds according to the invention deriving from heparin, these are prepared starting from heparin itself by means of desulphation techniques known to the technical experts in the field.
  • the desulphation is conducted in the presence of alkaline agents, such as sodium hydroxide, at temperatures ranging from ambient temperature to 100° C., preferably from 50 to 70° C., for example at 60° C., for a sufficiently long period to obtain the desired desulphation.
  • the desulphation is controlled by acting on the process parameters, such as the concentrations of reactants, the temperature and the reaction times.
  • One preferred example consists in maintaining constant concentrations of substrate (glycosaminoglycan) at 80 mg/ml and of NaOH at 1 M, a constant temperature of 60° C. and controlling the desulphation with a reaction time from 15 to 60 min.
  • the expert in the field may vary the conditions, for example by raising the reaction temperature and shortening the reaction time, on the basis of normal trial and error in experimental practice and on the basis of his or her general knowledge of the subject.
  • an intermediate product characterised by the presence of an epoxide ring on the desulphated unit gives rise to an intermediate product characterised by the presence of an epoxide ring on the desulphated unit.
  • these intermediates have proved to be endowed with antiangiogenic properties similar to those of the formula (I) compounds. Therefore, an further object of the invention described herein is a derivative of partially desulphated heparin, and therefore heparin with a reduced charge, particularly heparin not desulphated more than 60%, characterised by an epoxide ring on the desulphation site.
  • Said compounds characterised by an epoxide ring also belong to the objects covered by the present invention, that is to say the pharmaceutical compositions that contain them and their use for the preparation of medicaments with antiangiogenic activity.
  • heparin partially 2-O-desulphated obtainable by the process described above, where step a) is conducted for 15 min at 60° C. and step b) at 70° C. at pH 7, and with a molecular weight (MW) of 12900 D, a polydispersion index D of 1.5, a desulphation degree of 2.05 (expressed as the SO 3 ⁇ :COO ⁇ molar ratio), percentage of modified uronic acids compared to total uronic acids: 5% epoxide groups, 29% oxidated and reduced uronic residues (hereinafter called ST1513);
  • heparin partially 2-O-desulphated obtainable by the process described above, where step a) is conducted for 30 min at 60° C. and step b) at 70° C. at pH 7 (hereinafter called ST1516), and with a molecular weight (MW) of 11000 D, a polydispersion index D of 1.5, a desulphation degree of 1.8 (expressed as the SO 3 ⁇ :COO ⁇ molar ratio), percentage of modified uronic acids compared to total uronic acids. 5% epoxide groups, 29% oxidated and reduced uronic residues;
  • heparin partially 2-O-desulphated obtainable by the process described above, where step a) is conducted for 60 min at 60° C. and step b) at 70° C. at pH 7, and with a molecular weight (MW) of 9200 D, a polydispersion index D of 1.5, percentage of modified uronic acids compared to total uronic acids: 11% epoxide groups, 27.5% oxidated and reduced (split) uronic residues (hereinafter called ST1515).
  • the epoxide ring is opened, again resorting to known techniques.
  • the percentage of epoxide formed is calculated from the ratio between the areas of the 13 C-NMR signals at approximately 55 ppm, characteristic of carbons 2 and 3 of the uronic acid ring containing the epoxide and the total number of anomeric signals (C1 of the glucosamine and uronic acid residues). If the opening is conducted hot, a galacturonic acid residue is obtained, whereas, if the opening of the epoxide ring is conducted cold, an iduronic acid residue is obtained.
  • Preferred examples of compounds containing an epoxide ring are those obtainable by the process described above and having epoxidated uronic acid contents of 14% (hereinafter ST1509), 24% (hereinafter ST1525) and 30% (hereinafter ST1526), respectively.
  • formula (I) compounds can also be obtained without passing via the epoxide intermediate, that is to say by direct glycol split and subsequent Smith degradation.
  • the conjugation with amino acids or peptides can be done by treating the intermediate aldehyde derived from the glycol-split reaction with a reductive amination reaction (Hoffmann J. et al. Carbohydrate Research, 117, 328-331 (1983)), which can be conducted in aqueous solvent and is compatible with maintenance of the heparin structure.
  • a reductive amination reaction Hoffmann J. et al. Carbohydrate Research, 117, 328-331 (1983)
  • the formula (I) compounds can be further degraded with acid agents in suitable pH conditions, e.g. at pH 4, to yield a mixture of oligosaccharides that maintain the antiangiogenic properties.
  • objects of the present invention are the compounds obtained by one of the steps g), h), i) and j) of the process described above.
  • compositions containing as their active ingredient at least one formula (I) compound, alone or in combination with one or more formula (I) compounds, or, said formula (I) compound or compounds in combination with the desulphated heparins described above, e.g. the epoxidated intermediates; the latter can also be used alone as active ingredients in the pharmaceutical compositions.
  • the active ingredient according to the present invention will be in a mixture with suitable vehicles and/or excipients commonly used in pharmaceutical technology, such as, for instance, those described in “Remington's Pharmaceutical Sciences Handbook”, latest edition.
  • the compositions according to the present invention will contain a therapeutically effective quantity of the active ingredient.
  • the doses will be determined by the expert in the field, e.g. the clinician or primary care physician according to the type of disease to be treated and the patient's condition, or concomitantly with the administration of other active ingredients. By way of an example, doses ranging from 0.1 to 100 mg/kg may be indicated.
  • compositions are those that can be administered orally or parenterally, intravenously, intramuscularly, subcutaneously, transdermally or in the form of nasal or oral sprays.
  • Pharmaceutical compositions suitable for the purpose are tablets, hard or soft capsules, powders, solutions, suspensions, syrups, and solid forms for extemporary liquid preparations.
  • Compositions for parenteral administration are, for example, all the intramuscular, intravenous and subcutaneous injectable forms as well as solutions, suspensions and emulsions. Liposome formulations should also be mentioned.
  • the tablets also include forms for the controlled release of the active ingredient whether as oral administration forms, tablets coated with suitable layers, microencapsulated powders, complexes with cyclodextrins, depot forms, for example, subcutaneous forms, such as depot injections or implants.
  • the compounds according to the present invention are substantially devoid of the side effects typical of heparin.
  • the compounds according to the invention are substantially devoid of anticoagulant activity.
  • the expert in the field means no or only negligible activity from the point of view of clinical use.
  • bFGF or FGF-2
  • FGF or FGF-1
  • FGF FGF-1
  • Both proteins are members of a class of growth factors characterised by a high degree of affinity for heparin.
  • Other potent angiogenic inductors are VEGF, VEGF-B and VEGF-C. All three VEGF factors, like the FGFs, are expressed ubiquitously in the body.
  • bFGF binding to heparin or to fragments of heparan sulphate causes their dimerisation and the possibility of binding to their own receptor by activating the transduction pathway of the signal that activates the endothelial cell in both mitogenesis and differentiation.
  • the heparan sulphates of the CHO-745flg cells will bind to FGF, which in turn will bind to the CHO-K1 cells, establishing a bridge.
  • the binding that occurs is detectable as a result of the green fluorescence emitted by the CHO-745flg cells.
  • L6-WT1 cells (rat myoblasts transfected with FGFR-1) were seeded at a density of 25,000 cells/cm 2 in 48-well plates in DMEM+ 10% FCS. After 24 hours the cells were washed with serum-free medium and incubated for 48 hours with DMEM+ 0.5% FCS. The cells were then incubated for 16 hours with FGF-2 at the concentrations of 15 and 30 ng/ml in the presence or absence of the test compounds (all at 100 ⁇ g/ml). At the end of the incubation 3H-thymidine (0.25 ⁇ Ci/well) was added without changing the medium. After 6 hours, precipitable TCA was measured. Each experimental point is the mean of 3 determinations.
  • BAEC cells were seeded at a density of 2,500 cells/cm 2 in 48-well plates in EGM Bullet Kit complete medium. After 24 hours the cells were cultivated in the absence of serum in EGM medium without bovine brain extract and hFGF. After a further 24 hours, the cells were treated with 30 ng/ml of bFGF in the presence of increasing concentrations of the test compound. After 16 hours, 1 ⁇ Ci/ml of 3H-thymidine was added to the medium. After 6 hours, precipitable TCA activity was measured. Each experimental point is the mean of 8 determinations. The results are given in Tables 3-6.
  • BAEC cells at the 7th pass were seeded at a density of 2,500 cells/cm 2 in 96-well plates in EBM medium without bovine brain extract and hEGF. To this medium were added 30 ng/ml of FGF-2 and each of the test compounds at 5 concentrations ranging from 10 ng/ml to 100 ⁇ g/ml. After 3 days the cells were fixed and stained with crystal-violet and the optical density was determined by means of an ELISA microplate reader. Each experimental point was done in quadruplicate and the ID 50 was calculated. The results are given in Table 7. TABLE 7 Test of cell proliferation in BAEC Inhibition (ID 50 ) Product ⁇ g/ml Heparin 100 ST1509 0.02 ST1525 10 ST1526 0.02 ST1527 100 ST1528 0.1
  • GM7373 cells were seeded at a density of 70,000 cells/cm 2 in 96-well plates in MEM+ 10% FCS medium. After 24 hours, the cells were washed with serum-free medium and treated with 10 ng/ml of FGF-2 in medium containing 0.4% FCS. After 8 hours, the test compounds were added to the medium at 5 concentrations ranging from 10 ng/ml to 100 ⁇ g/ml. After a further 16 hours, the cells were trypsinised and counted in a Burker chamber. The ID 50 was calculated for each compound and the results are the means of 2 experiments in triplicate. The results are given in Table 8.
  • CAM chick embryo chorioallantoic membrane
  • Each molecule was resuspended in 3 ⁇ l of PBS at a concentration of 50 or 100 ⁇ g/embryo.
  • FGF-2 was used (1 ⁇ g/sponge), for which potent angiogenic activity on the CAM has been demonstrated (Ribatti e al., Dev. Biol. 170, 39, (1995)).
  • the sponges were first rested on the surface of the CAM, and then 3 ⁇ l of solution of the test substance were pipetted onto the surface of the sponge.
  • the CAMs were examined daily using a Zeiss SR stereomicroscope equipped with a photographic device.
  • mice 20 6-week-old female Balb/c mice weighing 20 g (Harlan), divided into groups by casual randomisation, were treated with heparin sodium, as a reference, and with the compound according to the present invention called ST1514.
  • the treatment schedule was of the q2dx5 type, i.e. 5 total administrations at intervals of 2 days, administering 200 ⁇ l/mouse of 50 mg/kg/10 ml and 25 mg/kg/10 ml solutions subcutaneously.
  • Heparin sodium the solution is prepared by solubilising 160 mg of powder in 4 ml of Ca ++ - and Mg ++ -free PBS 1 ⁇ pH 7.4; it is subdivided into aliquots of 243 ⁇ l and stored at ⁇ 20° C. At the time of treatment, the solution is diluted in Ca ++ - and Mg ++ -free PBS (Dulbecco, modified formula) 1 ⁇ , pH 7.4 so as to have the substance at final concentrations of 50 mg/kg/10 ml and 25 mg/kg/10 ml.
  • the solution is prepared by solubilising 160 mg of powder in 4 ml of Ca ++ - and Mg ++ -free PBS 1 ⁇ , pH 7.4; it is subdivided into aliquots of 243 ⁇ l and stored at ⁇ 20° C. At the time of treatment, the solution is diluted in Ca ++ - and Mg ++ -free PBS (Dulbecco, modified formula) 1 ⁇ , pH 7.4 so as to have the substance at final concentrations of 50 mg/kg/10 ml and 25 mg/kg/10 ml.
  • the compound was characterised by means of NMR spectroscopy (FIG. 1).
  • ST1513 molecular weight (MW) 12900 D, polydispersion index D 1.5, desulphation degree 2.05 (expressed as SO 3 —:COO— molar ratio), percentage of modified uronic acids compared to total uronic acids: 5% epoxide groups, 29% oxidated and reduced (split) uronic residues;
  • ST1516 molecular weight (MW) 12900 D, polydispersion index D 1.5, desulphation degree 1.8 (expressed as SO 3 ⁇ :COO ⁇ molar ratio), percentage of modified uronic acids compared to total uronic acids: 5% epoxide groups, 29% oxidated and reduced (split) uronic residues;
  • ST1515 molecular weight (MW) 9200 D, polydispersion index D 1.5, percentage of modified uronic acids compared to total uronic acids: 11% epoxide groups, 27.5% oxidated and reduced (split) uronic residues.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
US10/182,185 2000-01-25 2001-01-24 Derivatives of partially desulphated glycosaminologycans endowed with antiangiogenic activity and devoid of anticogulating effect Abandoned US20030013682A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US11/028,512 US7790700B2 (en) 2000-01-25 2005-01-04 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
US11/314,736 US7781416B2 (en) 2000-01-25 2005-12-22 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US11/882,978 US8067555B2 (en) 2000-01-25 2007-08-08 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US11/980,741 US20080139503A1 (en) 2000-01-25 2007-10-31 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US12/851,166 US8222231B2 (en) 2000-01-25 2010-08-05 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000RM000041A IT1316986B1 (it) 2000-01-25 2000-01-25 Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
ITRM2000A000041 2000-01-25

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/967,255 Continuation-In-Part US20050107331A1 (en) 2000-01-25 2004-10-19 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
US10/967,255 Continuation US20050107331A1 (en) 2000-01-25 2004-10-19 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect

Publications (1)

Publication Number Publication Date
US20030013682A1 true US20030013682A1 (en) 2003-01-16

Family

ID=11454382

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/182,185 Abandoned US20030013682A1 (en) 2000-01-25 2001-01-24 Derivatives of partially desulphated glycosaminologycans endowed with antiangiogenic activity and devoid of anticogulating effect
US10/967,255 Abandoned US20050107331A1 (en) 2000-01-25 2004-10-19 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
US11/028,512 Expired - Fee Related US7790700B2 (en) 2000-01-25 2005-01-04 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
US12/851,166 Expired - Fee Related US8222231B2 (en) 2000-01-25 2010-08-05 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect

Family Applications After (3)

Application Number Title Priority Date Filing Date
US10/967,255 Abandoned US20050107331A1 (en) 2000-01-25 2004-10-19 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
US11/028,512 Expired - Fee Related US7790700B2 (en) 2000-01-25 2005-01-04 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
US12/851,166 Expired - Fee Related US8222231B2 (en) 2000-01-25 2010-08-05 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect

Country Status (22)

Country Link
US (4) US20030013682A1 (de)
EP (1) EP1268558B1 (de)
JP (1) JP5371167B2 (de)
KR (1) KR100812406B1 (de)
CN (1) CN100540570C (de)
AT (1) ATE348115T1 (de)
AU (1) AU782632B2 (de)
BR (1) BR0107696A (de)
CA (1) CA2397964C (de)
CY (1) CY1108001T1 (de)
CZ (1) CZ303030B6 (de)
DE (1) DE60125154T2 (de)
DK (1) DK1268558T3 (de)
ES (1) ES2277911T3 (de)
HK (1) HK1051867A1 (de)
HU (1) HU229509B1 (de)
IT (1) IT1316986B1 (de)
MX (1) MXPA02007195A (de)
PL (1) PL209479B1 (de)
PT (1) PT1268558E (de)
SK (1) SK287566B6 (de)
WO (1) WO2001055221A1 (de)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298260A1 (en) * 2007-11-02 2010-11-25 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US20100316640A1 (en) * 2007-11-02 2010-12-16 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US20100324276A1 (en) * 2007-11-02 2010-12-23 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
US8871925B2 (en) 2011-12-28 2014-10-28 Galectin Therapeutics Inc. Compositions of novel carbohydrate drug for treatment of human diseases
EP2926818A1 (de) 2004-03-26 2015-10-07 La Jolla Pharmaceutical Company Modifizierte pektine, zusammensetzungen und zugehörige verfahren
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
US9387256B2 (en) 2010-04-16 2016-07-12 Momenta Pharmaceuticals, Inc. Tissue targeting
US9763974B2 (en) 2012-06-06 2017-09-19 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
US9872909B2 (en) 2012-09-17 2018-01-23 Galeotin Therapeutics, Inc. Method for enhancing specific immunotherapies in cancer treatment
US10017585B2 (en) 2010-06-17 2018-07-10 Momenta Pharmaceuticals, Inc. Methods and compositions for promoting hair growth
US10016449B2 (en) 2013-05-28 2018-07-10 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781416B2 (en) 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
AU2008202261B2 (en) * 2001-09-12 2011-07-28 Leadiant Biosciences S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
PT1427427E (pt) 2001-09-12 2011-09-13 Sigma Tau Res Switzerland Sa Derivados de glicosaminoglicanos parcialmente dessulfatados como inibidores da heparanase, dotados de actividade antiangiogénica e destituídos de efeito anticoagulante
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
CN101842392B (zh) * 2007-11-02 2014-08-27 动量制药公司 非抗凝血剂的多糖组合物
US8431826B2 (en) 2010-05-14 2013-04-30 James Robert Howard Capacitive power and ground plane structure utilizing fractal elements for the reduction of radiated emissions
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
ME02994B (de) 2011-12-19 2018-10-20 Dilafor Ab Nicht antikoagulative glykosaminoglykane mit sich wiederholender disaccharideinheit und ihre medizinische verwendung
US9507912B2 (en) 2012-08-31 2016-11-29 Nuvectra Corporation Method and system of simulating a pulse generator on a clinician programmer
JP6132302B2 (ja) * 2013-05-28 2017-05-24 リーディアント・バイオサイエンシーズ・ソシエタ・アノニマＬｅａｄｉａｎｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｓ．Ａ． 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体
ITLO20130005A1 (it) 2013-10-31 2015-05-01 He E Biochimiche G Ronzonr S R Derivati di glucosamminoglicani n-desolfatati e loro uso come farmaci
ITLO20130006A1 (it) 2013-11-06 2015-05-07 He E Biochimiche G Ronzoni S R Derivati carbossilati di glucosamminoglicani e loro uso come farmaci
CN103724458B (zh) * 2014-01-17 2016-03-30 福州大学 含n-非取代葡萄糖胺肝素六糖的制备及其纯化
US10576101B2 (en) 2015-03-06 2020-03-03 Leadiant Biosciences Sa Roneparstat combined therapy of multiple myeloma
JP2016014148A (ja) * 2015-09-10 2016-01-28 シグマ−タウ・リサーチ・スウィッツァーランド・ソシエテ・アノニム 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体
CN107177015A (zh) * 2016-03-11 2017-09-19 梁颖 一种重乙酰化肝素修饰物及其制备方法和应用
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CA3046997A1 (en) 2016-12-13 2018-06-21 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
US11225531B2 (en) 2018-02-02 2022-01-18 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Glycosaminoglycan derivative and preparation method therefor and use thereof
EP3705126A1 (de) 2019-03-05 2020-09-09 Leadiant Biosciences S.p.A. Roneparstat zur behandlung von amyloidose
CN114901702B (zh) * 2019-12-27 2024-01-09 深圳市海普瑞药业集团股份有限公司 一种糖胺聚糖衍生物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500519A (en) * 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
US5912237A (en) * 1992-07-24 1999-06-15 Carolinas Healthcare System Method of synthesis of desulfated heparin and use thereof for inhibition of elastase and cathespin
US20020010152A1 (en) * 1997-12-19 2002-01-24 Luigi De Ambrosi Composition consisting of heparin fractions having reproducible characteristics with average molecular weight equal to 5200d

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262403A (en) 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
IL79255A0 (en) 1986-06-26 1986-09-30 Hadassah Med Org Composition for metastasis prevention
AU7852687A (en) * 1986-08-21 1988-03-08 University Of Texas System, The Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
JPH05157344A (ja) * 1991-12-09 1993-06-22 Mitsubishi Heavy Ind Ltd 空気調和機の吹出口
JPH0512822A (ja) 1991-12-16 1993-01-22 Seiko Epson Corp カートリツジ
JPH06157344A (ja) * 1992-02-07 1994-06-03 Childrens Medical Center Corp:The 血管新生阻害のための医薬製剤及び血管新生阻害方法
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
IT1264709B1 (it) 1993-07-12 1996-10-04 Italfarmaco Spa Derivati eparinici ad attivita' antimetastatica
US5583121A (en) * 1994-01-12 1996-12-10 Michigan State University Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
JPH09512822A (ja) * 1994-05-06 1997-12-22 グリコメド・インコーポレイテッド Ｏ−脱硫酸化ヘパリン誘導体とその製造法および使用
IL114951A (en) * 1995-08-15 1999-08-17 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
NZ326354A (en) * 1996-01-15 1999-05-28 Janssen Pharmaceutica Nv 3-(substituted-1-piperazinyl)-6-(substituted-1,2,4-thiadiazol-5 -yl)-pyridazine derivatives and medicaments
JP4051099B2 (ja) * 1997-01-31 2008-02-20 生化学工業株式会社 低分子化ヘパリン、その製造法及び医薬組成物
IT1296581B1 (it) * 1997-11-28 1999-07-14 Istituto Scient Di Chimica E B Materiali polimerici non trombogenici e ad esaltata compatibilita' con fluidi e tessuti organici
US7781416B2 (en) * 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
IT1316986B1 (it) * 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500519A (en) * 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5912237A (en) * 1992-07-24 1999-06-15 Carolinas Healthcare System Method of synthesis of desulfated heparin and use thereof for inhibition of elastase and cathespin
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
US20020010152A1 (en) * 1997-12-19 2002-01-24 Luigi De Ambrosi Composition consisting of heparin fractions having reproducible characteristics with average molecular weight equal to 5200d

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2926818A1 (de) 2004-03-26 2015-10-07 La Jolla Pharmaceutical Company Modifizierte pektine, zusammensetzungen und zugehörige verfahren
US9351992B2 (en) 2007-11-02 2016-05-31 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US20100316640A1 (en) * 2007-11-02 2010-12-16 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US20100324276A1 (en) * 2007-11-02 2010-12-23 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US20100298260A1 (en) * 2007-11-02 2010-11-25 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US9358252B2 (en) 2007-11-02 2016-06-07 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US9212233B2 (en) 2007-11-02 2015-12-15 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US9387256B2 (en) 2010-04-16 2016-07-12 Momenta Pharmaceuticals, Inc. Tissue targeting
US10017585B2 (en) 2010-06-17 2018-07-10 Momenta Pharmaceuticals, Inc. Methods and compositions for promoting hair growth
US9974802B2 (en) 2011-12-28 2018-05-22 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
US8962824B2 (en) 2011-12-28 2015-02-24 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
US8871925B2 (en) 2011-12-28 2014-10-28 Galectin Therapeutics Inc. Compositions of novel carbohydrate drug for treatment of human diseases
US9649327B2 (en) 2011-12-28 2017-05-16 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
US10420793B2 (en) 2011-12-28 2019-09-24 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
US10799525B2 (en) 2011-12-28 2020-10-13 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
US11413303B2 (en) 2011-12-28 2022-08-16 Galectin Therapeutics, Inc. Methods for treatment of arthritis
US9763974B2 (en) 2012-06-06 2017-09-19 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
US9872909B2 (en) 2012-09-17 2018-01-23 Galeotin Therapeutics, Inc. Method for enhancing specific immunotherapies in cancer treatment
US10398778B2 (en) 2012-09-17 2019-09-03 Galectin Therapeutics, Inc. Method for enhancing specific immunotherapies in cancer treatment
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
US10016449B2 (en) 2013-05-28 2018-07-10 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
DE60125154D1 (de) 2007-01-25
HU229509B1 (en) 2014-01-28
HUP0204196A3 (en) 2003-05-28
SK287566B6 (sk) 2011-02-04
CZ303030B6 (cs) 2012-03-07
MXPA02007195A (es) 2003-01-28
CZ20022308A3 (cs) 2003-01-15
DE60125154T2 (de) 2007-10-25
CN1396930A (zh) 2003-02-12
WO2001055221A1 (en) 2001-08-02
ITRM20000041A0 (it) 2000-01-25
US7790700B2 (en) 2010-09-07
PT1268558E (pt) 2007-02-28
AU3406401A (en) 2001-08-07
SK10672002A3 (sk) 2002-12-03
ES2277911T3 (es) 2007-08-01
CY1108001T1 (el) 2013-09-04
US20050107331A1 (en) 2005-05-19
US8222231B2 (en) 2012-07-17
IT1316986B1 (it) 2003-05-26
AU782632B2 (en) 2005-08-18
CA2397964A1 (en) 2001-08-02
US20100298263A1 (en) 2010-11-25
BR0107696A (pt) 2002-10-15
KR100812406B1 (ko) 2008-03-11
HUP0204196A2 (hu) 2003-03-28
EP1268558B1 (de) 2006-12-13
DK1268558T3 (da) 2007-04-10
EP1268558A1 (de) 2003-01-02
JP2003523460A (ja) 2003-08-05
CN100540570C (zh) 2009-09-16
JP5371167B2 (ja) 2013-12-18
PL209479B1 (pl) 2011-09-30
US20050222084A1 (en) 2005-10-06
HK1051867A1 (en) 2003-08-22
CA2397964C (en) 2010-10-12
ITRM20000041A1 (it) 2001-07-25
KR20020080381A (ko) 2002-10-23
ATE348115T1 (de) 2007-01-15
PL357209A1 (en) 2004-07-26

Similar Documents

Publication Publication Date Title
EP1268558B1 (de) Teildesulfatierte glykosaminoglykanderivate mit antiangiogenischer aktivität und ohne antikoagulierender wirkung
US7781416B2 (en) Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
JP5816342B2 (ja) 非抗凝固性多糖組成物
US8592393B2 (en) Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
AU2001292231B2 (en) Derivatives of partially desulphated glycogaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
HUT59828A (en) Process for producing oligosaccharid-containing inhibitors of endothelial celle-multiplication and inhibitors of angiogenezis
WO2009059284A2 (en) Non-anticoagulant polysaccharide compositions
AU2001292231A1 (en) Derivatives of partially desulphated glycogaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US20080139503A1 (en) Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
AU2008202261B2 (en) Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect

Legal Events

Date Code Title Description
AS Assignment

Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CASU, BANITO;GIANGIACOMO, TORRI;NAGGI, ANNA MARIA;AND OTHERS;REEL/FRAME:013338/0427;SIGNING DATES FROM 20020617 TO 20020620

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION